366:
700:
29:
445:
70:
503:
487:
InChI=1S/C20H28I3N3O9/c1-9(29)26(5-12(32)8-35-2)18-16(22)13(19(33)24-3-10(30)6-27)15(21)14(17(18)23)20(34)25-4-11(31)7-28/h10-12,27-28,30-32H,3-8H2,1-2H3,(H,24,33)(H,25,34)
721:, meaning that the solution has a relatively low concentration of molecules; this is usually associated with fewer adverse effects than high-osmolality contrast agents.
576:
459:
865:
1374:
1190:
479:
638:, vomiting, headache, as well as low or high blood pressure or heart rate. Allergy-like reactions such as rashes are usually mild;
1433:
175:
100:
1418:
1323:
858:
285:
1391:
836:(in German). Vienna: Österreichischer Apothekerverlag. Imagopaque 150 mg J/ml-parenterale Röntgenkontrastmittellösung.
345:
748:
is very low. The substance is not metabolized, but excreted in unchanged form via the kidneys, exclusively by
1379:
1256:
851:
676:, can be less effective when used within two to six weeks after application of iopentol because of residual
51:
334:
124:
1428:
749:
588:
706:
of a patient with brain metastases from breast cancer, before (left) and after (right) injection of an
1096:
753:
713:
Iopentol is an iodine-containing, water-soluble radiocontrast agent. The iodine atoms readily absorb
144:
361:
1423:
1360:
1335:
741:
699:
646:
611:
528:
200:
62:
1271:
1172:
707:
694:
1284:
1279:
1220:
803:
41:
935:
600:
382:
116:
294:
274:
209:
1240:
1091:
1086:
1071:
1061:
945:
915:
874:
596:
584:
134:
365:
1385:
1245:
1230:
1195:
1158:
1081:
1051:
930:
920:
745:
725:
673:
650:
568:
1412:
1340:
1076:
1056:
990:
972:
950:
940:
907:
887:
623:
544:
532:
1355:
1349:
1293:
1261:
1225:
1210:
1181:
1137:
878:
669:
572:
83:
78:
234:
1331:
1235:
1205:
1142:
1122:
980:
703:
607:
58:
783:
1309:
1289:
1215:
1200:
1126:
1066:
1030:
718:
661:
552:
421:
265:
1344:
1020:
1000:
995:
955:
580:
564:
157:
807:
622:
Hysterosalpingography is contraindicated during acute inflammation in the
1118:
1025:
1010:
1005:
925:
796:-(2-hydroxyethyl-3-methoxypropyl)-acetamidol-2,4,6-triiodoisophthalamide"
548:
245:
20:
254:
1132:
1035:
985:
960:
843:
729:
728:
concluded that iopentol produces images of a similarly high quality as
665:
639:
560:
220:
714:
677:
635:
592:
325:
28:
314:
698:
642:
556:
444:
435:
305:
847:
717:, resulting in a higher contrast of X-ray images. It has a low
191:(2,3-dihydroxypropyl)-5--2,4,6-triiodobenzene-1,3-dicarboxamide
467:
CC(=O)N(CC(COC)O)c1c(c(c(c(c1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
740:
After intravenous injection, iopentol is distributed in the
350:
510:
800:
Molecular
Imaging and Contrast Agent Database (MICAD)
732:, and that it is equally well tolerated by patients.
1322:
1302:
1270:
1180:
1171:
1151:
1109:
1044:
969:
904:
895:
886:
433:
420:
381:
376:
344:
324:
304:
284:
264:
244:
219:
199:
166:
156:
143:
133:
123:
115:
99:
94:
69:
50:
40:
35:
233:
208:
577:endoscopic retrograde cholangiopancreatography
527:) is a pharmaceutical drug that was used as a
859:
8:
19:
1177:
901:
892:
866:
852:
844:
752:. Only 2% are excreted in the faeces. The
364:
273:
27:
293:
777:
775:
773:
771:
769:
765:
484:
464:
360:
253:
180:
18:
333:
7:
827:
825:
823:
821:
819:
817:
82:
313:
224:
14:
689:Chemistry and mechanism of action
708:iodine-containing contrast agent
405:
393:
492:Key:IUNJANQVIJDFTQ-UHFFFAOYSA-N
411:
399:
387:
65:, injection into body cavities
1:
792:´-Bis(2,3-dihydroxypropyl)-5-
1450:
692:
668:used for thyroid imaging (
610:or body cavities or given
377:Chemical and physical data
1369:
832:Haberfeld H, ed. (2020).
575:(imaging of the joints),
500:
475:
455:
171:
26:
634:Adverse effects include
1434:Iodobenzene derivatives
1257:Ferric ammonium citrate
710:
750:glomerular filtration
702:
693:Further information:
589:hysterosalpingography
1419:Radiocontrast agents
754:biological half-life
1361:Sulfur hexafluoride
742:extracellular space
606:It can be injected
529:radiocontrast agent
152:2 hrs (intravenous)
23:
1396:Never to phase III
711:
695:Iodinated contrast
608:into blood vessels
579:(ERCP; imaging of
1406:
1405:
1318:
1317:
1272:Superparamagnetic
1221:Gadopentetic acid
1167:
1166:
1105:
1104:
782:Cheng KT (2004).
744:. Its binding to
672:) and therapy of
618:Contraindications
518:
517:
446:Interactive image
346:CompTox Dashboard
16:Chemical compound
1441:
1354:Microspheres of
1191:Gadolinium-based
1178:
1097:Calcium iopodate
936:Ioxitalamic acid
902:
893:
868:
861:
854:
845:
838:
837:
829:
812:
811:
779:
736:Pharmacokinetics
664:, a radioactive
601:gastrointestinal
591:(imaging of the
567:(imaging of the
555:(imaging of the
514:
513:
506:
448:
428:
413:
407:
401:
395:
389:
369:
368:
354:
352:
337:
317:
297:
277:
257:
237:
227:
226:
212:
148:
86:
31:
24:
22:
1449:
1448:
1444:
1443:
1442:
1440:
1439:
1438:
1409:
1408:
1407:
1402:
1401:
1386:Clinical trials
1365:
1314:
1298:
1266:
1241:Gadoversetamide
1163:
1147:
1112:Water insoluble
1111:
1101:
1092:Tyropanoic acid
1087:Sodium iopodate
1072:Iobenzamic acid
1062:Ioglycamic acid
1040:
971:
965:
946:Acetrizoic acid
916:Diatrizoic acid
906:
897:
882:
872:
842:
841:
831:
830:
815:
781:
780:
767:
762:
746:plasma proteins
738:
697:
691:
686:
674:thyroid cancers
659:
632:
630:Adverse effects
620:
597:fallopian tubes
585:pancreatic duct
541:
509:
507:
504:(what is this?)
501:
496:
493:
488:
483:
482:
471:
468:
463:
462:
451:
426:
416:
410:
404:
398:
392:
372:
348:
340:
320:
300:
280:
260:
240:
223:
215:
195:
192:
179:
178:
162:98% via kidneys
146:
125:Protein binding
117:Pharmacokinetic
111:
90:
53:
17:
12:
11:
5:
1447:
1445:
1437:
1436:
1431:
1426:
1421:
1411:
1410:
1404:
1403:
1400:
1399:
1398:
1397:
1394:
1383:
1377:
1371:
1370:
1367:
1366:
1364:
1363:
1358:
1352:
1347:
1341:Microparticles
1338:
1328:
1326:
1320:
1319:
1316:
1315:
1313:
1312:
1306:
1304:
1300:
1299:
1297:
1296:
1287:
1282:
1276:
1274:
1268:
1267:
1265:
1264:
1259:
1249:
1248:
1246:Gadoxetic acid
1243:
1238:
1233:
1231:Gadoteric acid
1228:
1223:
1218:
1213:
1208:
1203:
1198:
1196:Gadobenic acid
1186:
1184:
1175:
1169:
1168:
1165:
1164:
1162:
1161:
1159:Barium sulfate
1155:
1153:
1149:
1148:
1146:
1145:
1140:
1135:
1130:
1119:Ethiodized oil
1115:
1113:
1107:
1106:
1103:
1102:
1100:
1099:
1094:
1089:
1084:
1082:Iocetamic acid
1079:
1074:
1069:
1064:
1059:
1054:
1052:Iodoxamic acid
1048:
1046:
1042:
1041:
1039:
1038:
1033:
1028:
1023:
1018:
1013:
1008:
1003:
998:
993:
988:
983:
977:
975:
967:
966:
964:
963:
958:
953:
948:
943:
938:
933:
931:Iotalamic acid
928:
923:
921:Metrizoic acid
918:
912:
910:
899:
890:
884:
883:
875:Contrast media
873:
871:
870:
863:
856:
848:
840:
839:
813:
764:
763:
761:
758:
756:is two hours.
737:
734:
726:clinical trial
690:
687:
685:
682:
658:
655:
651:cardiac arrest
631:
628:
619:
616:
569:urinary system
543:Uses included
540:
537:
516:
515:
498:
497:
495:
494:
491:
489:
486:
478:
477:
476:
473:
472:
470:
469:
466:
458:
457:
456:
453:
452:
450:
449:
441:
439:
431:
430:
424:
418:
417:
414:
408:
402:
396:
390:
385:
379:
378:
374:
373:
371:
370:
362:DTXSID40869032
357:
355:
342:
341:
339:
338:
330:
328:
322:
321:
319:
318:
310:
308:
302:
301:
299:
298:
290:
288:
282:
281:
279:
278:
270:
268:
262:
261:
259:
258:
250:
248:
242:
241:
239:
238:
230:
228:
217:
216:
214:
213:
205:
203:
197:
196:
194:
193:
182:
174:
173:
172:
169:
168:
164:
163:
160:
154:
153:
150:
141:
140:
137:
131:
130:
127:
121:
120:
113:
112:
110:
109:
105:
103:
97:
96:
92:
91:
89:
88:
75:
73:
67:
66:
56:
54:administration
48:
47:
44:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
1446:
1435:
1432:
1430:
1427:
1425:
1422:
1420:
1417:
1416:
1414:
1395:
1393:
1390:
1389:
1387:
1384:
1381:
1378:
1376:
1373:
1372:
1368:
1362:
1359:
1357:
1356:phospholipids
1353:
1351:
1348:
1346:
1342:
1339:
1337:
1336:human albumin
1333:
1330:
1329:
1327:
1325:
1321:
1311:
1308:
1307:
1305:
1301:
1295:
1294:nanoparticles
1291:
1288:
1286:
1283:
1281:
1278:
1277:
1275:
1273:
1269:
1263:
1260:
1258:
1254:
1251:
1250:
1247:
1244:
1242:
1239:
1237:
1234:
1232:
1229:
1227:
1224:
1222:
1219:
1217:
1214:
1212:
1209:
1207:
1204:
1202:
1199:
1197:
1193:
1192:
1188:
1187:
1185:
1183:
1179:
1176:
1174:
1170:
1160:
1157:
1156:
1154:
1152:Non-iodinated
1150:
1144:
1141:
1139:
1136:
1134:
1131:
1128:
1124:
1120:
1117:
1116:
1114:
1108:
1098:
1095:
1093:
1090:
1088:
1085:
1083:
1080:
1078:
1077:Iopanoic acid
1075:
1073:
1070:
1068:
1065:
1063:
1060:
1058:
1057:Iotroxic acid
1055:
1053:
1050:
1049:
1047:
1043:
1037:
1034:
1032:
1029:
1027:
1024:
1022:
1019:
1017:
1014:
1012:
1009:
1007:
1004:
1002:
999:
997:
994:
992:
991:Ioxaglic acid
989:
987:
984:
982:
979:
978:
976:
974:
970:Nephrotropic,
968:
962:
959:
957:
954:
952:
951:Iocarmic acid
949:
947:
944:
942:
941:Ioglicic acid
939:
937:
934:
932:
929:
927:
924:
922:
919:
917:
914:
913:
911:
909:
905:Nephrotropic,
903:
900:
898:Water soluble
894:
891:
889:
885:
880:
876:
869:
864:
862:
857:
855:
850:
849:
846:
835:
834:Austria-Codex
828:
826:
824:
822:
820:
818:
814:
809:
805:
801:
797:
795:
791:
787:
778:
776:
774:
772:
770:
766:
759:
757:
755:
751:
747:
743:
735:
733:
731:
727:
722:
720:
716:
709:
705:
701:
696:
688:
683:
681:
680:in the body.
679:
675:
671:
667:
663:
656:
654:
652:
648:
644:
641:
637:
629:
627:
625:
624:pelvic region
617:
615:
613:
609:
604:
602:
598:
594:
590:
586:
582:
578:
574:
570:
566:
563:enhancement,
562:
558:
554:
550:
546:
545:arteriography
538:
536:
534:
533:X-ray imaging
530:
526:
522:
512:
505:
499:
490:
485:
481:
474:
465:
461:
454:
447:
443:
442:
440:
437:
432:
425:
423:
419:
386:
384:
380:
375:
367:
363:
359:
358:
356:
347:
343:
336:
335:ChEMBL2104783
332:
331:
329:
327:
323:
316:
312:
311:
309:
307:
303:
296:
292:
291:
289:
287:
283:
276:
272:
271:
269:
267:
263:
256:
252:
251:
249:
247:
243:
236:
232:
231:
229:
222:
218:
211:
207:
206:
204:
202:
198:
190:
186:
181:
177:
170:
165:
161:
159:
155:
151:
149:
142:
138:
136:
132:
128:
126:
122:
118:
114:
107:
106:
104:
102:
98:
93:
85:
80:
77:
76:
74:
72:
68:
64:
60:
57:
55:
49:
45:
43:
39:
36:Clinical data
34:
30:
25:
1429:Acetanilides
1350:Perflenapent
1332:Microspheres
1262:Mangafodipir
1252:
1226:Gadopiclenol
1211:Gadofosveset
1189:
1182:Paramagnetic
1138:Propyliodone
1123:Ethyl esters
1045:Hepatotropic
1015:
908:high osmolar
888:X-ray and CT
833:
799:
793:
789:
785:
739:
724:A phase III
723:
712:
684:Pharmacology
670:scintigraphy
660:
657:Interactions
633:
621:
605:
573:arthrography
547:(imaging of
542:
539:Medical uses
524:
523:(trade name
520:
519:
508:
502:
188:
184:
145:Elimination
101:Legal status
95:Legal status
1382:from market
1236:Gadoteridol
1206:Gadodiamide
1143:Iofendylate
1129:, lipiodol)
1127:fatty acids
1125:of iodised
981:Metrizamide
973:low osmolar
704:Contrast CT
535:in Europe.
429: g·mol
167:Identifiers
59:Intravenous
42:Trade names
1424:Benzamides
1413:Categories
1324:Ultrasound
1310:Perflubron
1290:Iron oxide
1285:Ferristene
1280:Ferumoxsil
1216:Gadolinium
1201:Gadobutrol
1110:Iodinated,
1067:Adipiodone
1031:Iobitridol
896:Iodinated,
760:References
719:osmolality
662:Iodine-131
653:are rare.
553:venography
525:Imagopaque
434:3D model (
422:Molar mass
295:7D6XWX076T
266:ChemSpider
210:89797-00-2
201:CAS Number
176:IUPAC name
135:Metabolism
46:Imagopaque
1392:Phase III
1380:Withdrawn
1345:galactose
1021:Iodixanol
1001:Iopromide
996:Iopamidol
956:Methiodal
603:studies.
565:urography
158:Excretion
147:half-life
108:Withdrawn
52:Routes of
1026:Iomeprol
1016:Iopentol
1011:Ioversol
1006:Iotrolan
926:Iodamide
808:20641971
612:by mouth
549:arteries
521:Iopentol
511:(verify)
246:DrugBank
71:ATC code
63:by mouth
21:Iopentol
1133:Iopydol
1036:Ioxilan
986:Iohexol
961:Diodone
730:iohexol
666:isotope
640:glottal
599:), and
561:CT scan
427:835.169
383:Formula
255:DB13861
221:PubChem
87:)
81: (
79:V08AB08
1375:WHO-EM
806:
715:X-rays
678:iodine
636:nausea
593:uterus
559:) and
460:SMILES
326:ChEMBL
315:D04582
1303:Other
1253:Other
647:shock
643:edema
557:veins
480:InChI
436:JSmol
275:50573
235:56016
189:N-bis
804:PMID
649:and
595:and
583:and
581:bile
531:for
306:KEGG
286:UNII
139:None
119:data
1343:of
1334:of
1173:MRI
1121:(=
879:V08
587:),
571:),
551:),
351:EPA
225:CID
187:,3-
129:Low
84:WHO
1415::
1388::
1292:,
1255::
1194::
816:^
802:.
798:.
768:^
645:,
626:.
614:.
397:28
391:20
183:1-
61:,
881:)
877:(
867:e
860:t
853:v
810:.
794:N
790:N
788:,
786:N
784:"
438:)
415:9
412:O
409:3
406:N
403:3
400:I
394:H
388:C
353:)
349:(
185:N
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
